The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PARP-1 inhibitor MK-4827 in combination with radiation as a treatment strategy for metastatic neuroblastoma.
S. Bhargava
No relevant relationships to disclose
S. Mueller
No relevant relationships to disclose
L. Wehmeijer
No relevant relationships to disclose
X. Yang
No relevant relationships to disclose
A. Gragg
No relevant relationships to disclose
K. K. Matthay
No relevant relationships to disclose
W. A. Weiss
No relevant relationships to disclose
D. A. Haas-Kogan
No relevant relationships to disclose